Previous Close | 73.93 |
Open | 74.09 |
Bid | 0.00 x 800 |
Ask | 74.07 x 1000 |
Day's Range | 72.05 - 74.88 |
52 Week Range | 38.86 - 102.99 |
Volume | |
Avg. Volume | 176,380 |
Market Cap | 1.91B |
Beta (5Y Monthly) | 0.88 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.48 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 102.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for KRYS
FDA granted Priority Review designationPDUFA target action date is February 17, 2023FDA stated that it is not currently planning to hold an advisory committee meeting PITTSBURGH, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the US Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for B-VEC for the treatment of patients with dystrophic ep
Biologics License Application for B-VEC filed with the FDA on June 22, 2022FDA accepts IND on KB407 for the treatment of Cystic FibrosisStrong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments PITTSBURGH, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational progress updates for the second quarter ending June 30, 2022. “The B
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis (CF). KB40